Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions

Heterobifunctional degraders, known as proteolysis targeting chimeras (PROTACs), theoretically possess a catalytic mode-of-action, yet few studies have either confirmed or exploited this potential advantage of event-driven pharmacology. Degraders of oncogenic EML4-ALK fusions were developed by conju...

Full description

Bibliographic Details

Published in:	Journal of medicinal chemistry Vol. 66; no. 8; p. 5524
Main Authors:	Gao, Yang, Jiang, Baishan, Kim, Hellen, Berberich, Matthew J, Che, Jianwei, Donovan, Katherine A, Hatcher, John M, Huerta, Fidel, Kwiatkowski, Nicholas P, Liu, Yingpeng, Liuni, Peter P, Metivier, Rebecca J, Murali, Vineeth K, Nowak, Radosław P, Zhang, Tinghu, Fischer, Eric S, Gray, Nathanael S, Jones, Lyn H
Format:	Journal Article
Language:	English
Published:	United States 27.04.2023
Subjects:	Anaplastic Lymphoma Kinase Antineoplastic Agents - pharmacology Drug Resistance, Neoplasm Humans Lung Neoplasms - drug therapy Mutation Oncogene Proteins, Fusion - genetics Protein Kinase Inhibitors - pharmacology Receptor Protein-Tyrosine Kinases
ISSN:	1520-4804, 1520-4804
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!